KRAS and neoplasm: Finally, to assess whether the observed upregulation of the PCD mediators is induced by mutant KRAS, we treated our acinar explants during our 3-day in vitro ADM assay with the recently developed, KRASG12D-specific inhibitor MRTX1133 that has shown anti-tumor efficacy in several PDAC mouse models23–25.